Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study.
Alcohol use disorder
Aldosterone
Cortisol
Craving
Ghrelin
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
05
05
2019
revised:
25
06
2019
accepted:
12
07
2019
pubmed:
17
7
2019
medline:
21
7
2020
entrez:
17
7
2019
Statut:
ppublish
Résumé
Increasing evidence supports the role of appetite-regulating hormones, including ghrelin, in alcohol use disorder (AUD). Effects of ghrelin administration on cortisol and aldosterone, two hormones known to influence the development and maintenance of AUD, have been observed in ghrelin-exposed tissues or cells, as well as rodents and healthy volunteers, however whether these effects replicate in individuals with AUD is unknown. Here, we tested the hypothesis that intravenous administration of ghrelin leads to increase in endogenous serum cortisol and aldosterone concentrations in alcohol-dependent, heavy drinking individuals, and that these changes may predict ghrelin-induced alcohol craving. This was a double-blind, placebo-controlled human laboratory study in non-treatment-seeking, heavy-drinking, alcohol-dependent individuals randomized to receive either placebo, 1 mcg/kg or 3 mcg/kg of intravenous ghrelin. Then, participants underwent a cue-reactivity procedure in a bar-like setting, which included exposure to both neutral (juice) and alcohol cues. Repeated blood samples were collected and used to measure endogenous cortisol and aldosterone serum concentrations, in response to exogenous ghrelin administration. Furthermore, cortisol and aldosterone serum concentrations were used to develop a model to predict the effect of exogenous ghrelin administration on alcohol craving. Intravenous ghrelin administration increased endogenous cortisol and aldosterone serum concentrations. While the effects on cortisol were greater than those on aldosterone, only the ghrelin-induced changes in aldosterone serum concentrations predicted craving. These findings provide initial evidence of ghrelin effects on glucocorticoids and mineralocorticoids in individuals with AUD, thereby providing additional information on the potential mechanisms by which the ghrelin system may play a role in alcohol craving and seeking in AUD.
Identifiants
pubmed: 31310775
pii: S0028-3908(19)30269-2
doi: 10.1016/j.neuropharm.2019.107711
pmc: PMC6745267
mid: NIHMS1535113
pii:
doi:
Substances chimiques
Ghrelin
0
Aldosterone
4964P6T9RB
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
107711Subventions
Organisme : NIAAA NIH HHS
ID : K01 AA023867
Pays : United States
Organisme : NIAAA NIH HHS
ID : R21 AA019709
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AA000218
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Endocr Connect. 2017 Nov;6(8):847-855
pubmed: 29038331
Mol Psychiatry. 2018 Oct;23(10):2029-2038
pubmed: 29133954
Int Rev Neurobiol. 2017;136:89-119
pubmed: 29056157
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
Neuroendocrinology. 2001 Sep;74(3):143-7
pubmed: 11528215
J Clin Invest. 2006 Dec;116(12):3229-39
pubmed: 17060947
Transl Psychiatry. 2015 Sep 29;5:e646
pubmed: 26418274
Alcohol Health Res World. 1998;22(1):67-72
pubmed: 15706736
Nature. 2000 Oct 19;407(6806):908-13
pubmed: 11057670
Future Neurol. 2010 May 1;5(3):393-401
pubmed: 20563312
Peptides. 2011 Jun;32(6):1281-8
pubmed: 21514337
Eur J Endocrinol. 2017 Feb;176(2):123-132
pubmed: 27913606
Neuropsychopharmacology. 2012 Mar;37(4):906-18
pubmed: 22048462
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6320-5
pubmed: 18443287
Eur J Pharmacol. 2000 Sep 29;405(1-3):103-12
pubmed: 11033318
Pituitary. 2004;7(4):243-8
pubmed: 16132204
Psychoneuroendocrinology. 2013 May;38(5):648-58
pubmed: 22980941
Int J Neuropsychopharmacol. 2016 May 10;19(10):
pubmed: 27207912
Brain Res. 2003 Nov 21;991(1-2):26-33
pubmed: 14575873
Peptides. 2012 Jun;35(2):149-59
pubmed: 22543218
Nature. 1999 Dec 9;402(6762):656-60
pubmed: 10604470
Alcohol. 2008 Aug;42(5):375-81
pubmed: 18486430
Peptides. 2009 Aug;30(8):1448-55
pubmed: 19416745
Regul Pept. 2012 Feb 10;174(1-3):12-7
pubmed: 22120831
CNS Drugs. 2014 Oct;28(10):875-86
pubmed: 24958205
ScientificWorldJournal. 2006 Jan 17;6:1-11
pubmed: 16432622
Physiol Behav. 2019 May 15;204:49-57
pubmed: 30738971
J Neurosci. 2004 Mar 17;24(11):2825-31
pubmed: 15028776
Horm Metab Res. 2003 Aug;35(8):455-9
pubmed: 12953161
Endocrinology. 1985 Dec;117(6):2505-11
pubmed: 2998738
J Clin Invest. 1973 Sep;52(9):2272-7
pubmed: 4353776
Curr Opin Pharmacol. 2013 Dec;13(6):977-82
pubmed: 24091195
CNS Drugs. 2014 Apr;28(4):343-60
pubmed: 24573997
Neuropsychopharmacology. 2013 Jan;38(2):364-75
pubmed: 22968812
J Abnorm Psychol. 2000 Nov;109(4):738-42
pubmed: 11195999
J Clin Endocrinol Metab. 1991 Jun;72(6):1290-5
pubmed: 2026749
Biol Psychiatry. 2014 Nov 1;76(9):734-41
pubmed: 24775991
Curr Pharm Des. 2010;16(19):2149-58
pubmed: 20482505
Psychopharmacology (Berl). 1996 Sep;127(2):133-9
pubmed: 8888379
Eur J Neurosci. 2008 Oct;28(8):1641-53
pubmed: 18979677
Mol Psychiatry. 2018 Jun;23(6):1466-1473
pubmed: 28461696
Drug News Perspect. 2010 Apr;23(3):157-66
pubmed: 20440417
Science. 1997 Oct 3;278(5335):52-8
pubmed: 9311926
Front Psychiatry. 2013 Aug 08;4:86
pubmed: 23964247
Alcohol Clin Exp Res. 2018 May 24;:
pubmed: 29797564
Gen Physiol Biophys. 2010 Jun;29(2):194-202
pubmed: 20577031
Alcohol Clin Exp Res. 2001 Aug;25(8):1134-9
pubmed: 11505044
Alcohol Res. 2012;34(4):468-83
pubmed: 23584113
Stress. 2011 Sep;14(5):520-9
pubmed: 21438782
J Clin Invest. 2015 Aug 3;125(8):3193-7
pubmed: 26121746